CINECA IRIS Institutional Research Information System

BERTANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.376
AS - Asia 1.908
EU - Europa 1.434
SA - Sud America 511
AF - Africa 121
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.373
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.281
SG - Singapore 683
CN - Cina 450
IT - Italia 426
BR - Brasile 425
HK - Hong Kong 354
SE - Svezia 215
DE - Germania 164
VN - Vietnam 148
GB - Regno Unito 125
BG - Bulgaria 116
AT - Austria 82
FR - Francia 73
FI - Finlandia 60
IN - India 59
RU - Federazione Russa 58
CA - Canada 56
CI - Costa d'Avorio 43
TR - Turchia 41
NL - Olanda 33
AR - Argentina 29
JP - Giappone 29
MX - Messico 26
PL - Polonia 23
NG - Nigeria 22
SN - Senegal 22
BD - Bangladesh 21
AU - Australia 19
EC - Ecuador 18
ID - Indonesia 17
IQ - Iraq 16
IR - Iran 10
PK - Pakistan 10
UZ - Uzbekistan 10
ZA - Sudafrica 9
BE - Belgio 8
ES - Italia 8
UA - Ucraina 8
VE - Venezuela 8
CO - Colombia 7
KR - Corea 7
PY - Paraguay 7
SA - Arabia Saudita 7
UY - Uruguay 7
JO - Giordania 6
LT - Lituania 6
MY - Malesia 6
PE - Perù 6
EG - Egitto 5
MA - Marocco 5
NP - Nepal 5
CH - Svizzera 4
JM - Giamaica 4
KE - Kenya 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
CL - Cile 3
EU - Europa 3
IL - Israele 3
KZ - Kazakistan 3
QA - Qatar 3
SI - Slovenia 3
AL - Albania 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
ET - Etiopia 2
GH - Ghana 2
KG - Kirghizistan 2
KH - Cambogia 2
MD - Moldavia 2
PA - Panama 2
PH - Filippine 2
PT - Portogallo 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
IE - Irlanda 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MR - Mauritania 1
MV - Maldive 1
NA - Namibia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
Totale 7.370
Salva come PNG Salva come JPEG
Città #
Ashburn 454
Dallas 364
Hong Kong 348
Singapore 320
Santa Clara 305
Fairfield 231
Chandler 206
Woodbridge 152
Shanghai 151
Ann Arbor 126
Sofia 116
Houston 114
New York 96
Seattle 89
Wilmington 85
Cambridge 84
Los Angeles 79
Boardman 75
Serra 74
Beijing 73
London 67
Vienna 63
Princeton 62
Florence 61
Lawrence 53
Milan 47
Munich 47
Abidjan 43
Medford 42
Ho Chi Minh City 38
Frankfurt am Main 36
São Paulo 31
Redondo Beach 30
Pisa 28
Istanbul 26
Ottawa 24
Tokyo 23
Dakar 22
Lagos 22
Helsinki 21
Buffalo 20
Bremen 19
Turku 18
Hanoi 17
Lucca 15
Redmond 15
Dearborn 14
Nuremberg 14
San Diego 14
Denver 13
Des Moines 13
Dong Ket 13
Toronto 12
Warsaw 12
Falkenstein 10
Groningen 10
Rome 10
Tashkent 10
Amsterdam 9
Belo Horizonte 9
Guayaquil 9
Lappeenranta 9
Nanjing 9
Ogden 9
Orem 9
Phoenix 9
Redwood City 9
Baghdad 8
Boulder 8
Brussels 8
Izmir 8
Montignoso 8
Montreal 8
Norwalk 8
Rio de Janeiro 8
Stockholm 8
Changsha 7
Chicago 7
Dhaka 7
Düsseldorf 7
Haiphong 7
Kent 7
Mexico City 7
Montevideo 7
Naples 7
Quanzhou 7
Amman 6
Brooklyn 6
Hebei 6
Kunming 6
Lauterbourg 6
Nanchang 6
Porto Alegre 6
Thái Bình 6
Washington 6
Biên Hòa 5
Brasília 5
Campinas 5
Charlotte 5
Grosseto 5
Totale 4.879
Salva come PNG Salva come JPEG
Nome #
Lactobacillus Casei DG® in Patients with Irritable Bowel Syndrome: Not Only a Change of the Gut Microbiota. A Pilot Study 219
Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease 193
Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients 192
Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? 175
Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique 173
Irritable bowel syndrome and chronic constipation: Fact and fiction 171
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 171
Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: A comparative study 166
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 166
Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring 165
Barrett's esophagus in 2016: From pathophysiology to treatment 160
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure 159
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 158
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 155
Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults 155
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 151
Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn 148
Esophageal testing: What we have so far 147
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 146
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 145
Intestinal histomorphological and molecular alterations in patients with Parkinson's disease 143
Oral sucrosomial iron is as effective as intravenous ferric carboxy‐maltose in treating anemia in patients with ulcerative colitis 142
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD 140
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 135
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 134
A low-FODMAP diet for irritable bowel syndrome: Some answers to the doubts from a long-term follow-up 133
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 132
Are PPI responder patients always confirmed as GERD patients? A MII-PH study. 131
Low fermentable oligo-di-and mono-saccharides and polyols (Fodmaps) or gluten free diet: What is best for irritable bowel syndrome? 130
Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study 126
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 124
Fecal calprotectin: Current and future perspectives for inflammatory bowel disease treatment 117
The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment 109
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 109
HOSPITALIZATION FOR DRUG INFUSION DOES NOT INCREASE COVID INFECTION RATE, IBD RELAPSES DUE TO INFECTIONS AND LEVELS OF ANXIETY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY 106
Esophageal bolus contact time and chemical clearance may differentiate patients with non-erosive reflux disease: an impedance-pH monitoring study 104
From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting 100
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry 99
Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study 96
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 94
Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak 92
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn's Disease Treated With Anti-TNF-α Biologics 92
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 87
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply 83
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply 82
Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF 81
Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study 80
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 76
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients 74
Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy 73
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 72
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? 72
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 71
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 71
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 69
Ig Glycosylation in Ulcerative Colitis: It’s Time for New Biomarkers 65
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 65
Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: An observational multicentre study 64
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study 64
Vitamin d-related genetics as predictive biomarker of clinical remission in adalimumab-treated patients affected by crohn’s disease: A pilot study 63
P965 Ulcerative proctitis treated with biologics: is it too hard to treat? 62
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem? 62
Ulcerative proctitis treated with biologics: is it too hard to treat? 60
Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue 53
null 49
Totale 7.501
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.701
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.701
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021233 0 0 0 0 0 10 37 19 50 18 49 50
2021/2022588 6 21 25 28 102 80 36 29 39 28 53 141
2022/2023886 103 151 85 53 89 95 15 57 166 2 70 0
2023/2024571 37 39 97 32 68 90 50 24 8 18 40 68
2024/20252.353 8 69 61 150 190 254 192 104 282 292 213 538
2025/20261.705 168 303 426 346 299 163 0 0 0 0 0 0
Totale 7.501